Candel Therapeutics, Inc. (NASDAQ:CADL) Financings

Candel Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Announced: US$100M · US$5.45 a share · Citigroup +5
Dealers: LifeSci Capital (lead), Citigroup (co-lead), Cantor (co-lead), Stifel (co-lead), H.C. Wainwright & Co., Brookline Capital Markets
Use of proceeds: Launch readiness and commercial activities for aglatimagene in prostate cancer, phase 3 NSCLC trial costs, and general corporate purposes
Feb 20, 2026
Registered direct offering of common stock
Announced: about US$15M · US$4.67 a share
Insiders: Investors include executive officers and members of the Company's Board of Directors.
Use of proceeds: Launch readiness, medical affairs and pre-commercialization for CAN-2409 in prostate cancer ahead of a BLA submission, and general corporate purposes
Jun 24, 2025
Public offering of common stock and pre-funded warrants
Closed: US$92M raised · US$6 a share · Citigroup +3
Dealers: Citigroup (co-lead), BofA Securities (co-lead), Canaccord Genuity (co-lead), H.C. Wainwright & Co.
Use of proceeds: Continue development of product candidates, including preparing a BLA submission for CAN-2409 in prostate cancer, and general corporate purposes
Dec 16, 2024

Read by 6ix AI from the company's releases